Clinical and psychosocial remission in schizophrenia: correlations with antipsychotic treatment
1 Psychiatry Department, Sackler School of Medicine, Tel-Aviv University, 12 H Levanon Street, Tel-Aviv, 69978, Israel
2 Department E, Geha Mental Health Center, 1 Helsinki Street, Tel-Aviv, 49100, Israel
3 Psychogeriatric Department, Abarbanel Mental Health Center, 15 KKL Street, Bat-Yam, 59100, Israel
BMC Psychiatry 2012, 12:108 doi:10.1186/1471-244X-12-108Published: 10 August 2012
Clinical and psychosocial remission amongst persons with schizophrenia is nowadays a defined goal of treatment. This necessitates incorporating quantifiable psychosocial variables with traditional symptomatic data. We aimed to assess clinical and psychosocial remission in schizophrenia in a large cohort of community dwelling persons with schizophrenia. We emphasized between-groups comparison of antipsychotic medications and administration methods on the outcome of remission.
Psychiatric case managers rated psychosocial remission using the PsychoSocial Remission Scale (PSRS) and clinical remission using the Remission in Schizophrenia Working Group symptomatic remission criteria (RSWG). Ratings were performed for persons with schizophrenia they have been treating for 6 months or more. Data as to gender, age and pharmacological treatment of each patient were also collected.
Of 445 participants who completed the survey, 268 (60%) were evaluated by psychiatrists, 161 (36%) by nurses and 16 (4%) were evaluated by social workers. Patients mean age was 43.4
In a large national sample a third of persons with schizophrenia were in remission. IM long acting preparations were associated with higher remission rates. Treatment choice may thus influence rates of remission in persons with schizophrenia.